.zhanglabpeople > div { margin-bottom: 2rem; } .zhanglabpeople > div img { width: 150px; float: left; margin-right: 1rem; aspect-ratio: 8 / 10; object-fit: cover; }

View Dr. Zhang’s complete list of published work in NCBI MyBibliography

1. Ahmari N, Choi K, Wu J, Rizvi TA, Jackson M, Kershner LJ, Kim MO, Zhang X, Dombi E, Shern J, Hildeman DA, Ratner N. Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas. Life Sci Alliance. 2025 Dec;8(12). doi: 10.26508/lsa.202503359. Print 2025 Dec. PubMed PMID: 40992926; PubMed Central PMCID: PMC12461152. 

.zhanglabaims { background-color: rgba(245, 245, 245, 1); padding: 1rem; border-radius:1rem; border: 1px solid #ccc; }

Research Overview

The Molecular Cancer Prevention Laboratory, led by Dr. Xiyuan Zhang at the Rutgers Cancer Institute, leverages genome-wide sequencing technologies to decipher the etiology and progression of pediatric sarcomas and cancer predisposition syndromes, particularly neurofibromatosis type 1 (NF1).

During cancer treatment, proper nutrition enhances the body's ability to fight the disease and improves treatment outcomes. For survivors, maintaining a balanced diet helps manage long-term side effects and improves quality of life.